Research and Clinical Trials on Atomoxetine (Strattera)

By Dr Greg Mulhauser
avatar image

This list of current clinical research trials on Atomoxetine (Strattera) is followed by a short set of abstracts from the most recent research articles published on the drug.

Article Contents

Atomoxetine (Strattera) Clinical Research Trials

From our searchable database at ClinicalTrialsFeeds.org, this list includes all the latest information about clinical trials involving Atomoxetine (Strattera).

 

Get These Clinical Trials as a Newsfeed

Atomoxetine:     Get the Atomoxetine clinical trials feed.    Add the Atomoxetine clinical trials feed to your My Yahoo! page.    Add the Atomoxetine clinical trials feed to your MyMSN page.

Current Research Literature on Atomoxetine (Strattera)

Here are abstracts for some of the latest research articles to have appeared on Atomoxetine (Strattera):

Effects of atomoxetine on cognitive function and cigarette smoking in schizophrenia.

Schizophr Res. 2008 Nov 6;
Sacco KA, Creeden C, Reutenauer EL, Vessicchio JC, Weinberger AH, George TP

[ADHD in adults]

Ugeskr Laeger. 2008 Oct 20; 170(43): 3395-9
Thomsen PH, Damm D
According to epidemiological surveys 1-2% of the adult population fulfil the criteria for attention-deficit hyperactivity disorder. Some need treatment which they are not currently offered. The effect of either central stimulants or atomoxetine is well established. Many patients need psychosocial intervention as a supplement to medication. Because of the differential diagnostic problems and the frequent occurrence of comorbid symptoms, examination is a specialist assignment in most cases.

Synthesis and activity of novel 1- or 3-(3-amino-1-phenyl propyl)-1,3-dihydro-2H-benzimidazol-2-ones as selective norepinephrine reuptake inhibitors.

Bioorg Med Chem Lett. 2008 Dec 1; 18(23): 6067-70
Zhang P, Terefenko EA, McComas CC, Mahaney PE, Vu A, Trybulski E, Koury E, Johnston G, Bray J, Deecher D
A series of novel 1- or 3-(3-amino-1-phenyl propyl)-1,3-dihydro-2H-benzimidazol-2-ones as selective norepinephrine reuptake inhibitors was discovered. Several compounds such as 15 and 20 showed good hNET potency. Compounds 15 and 20 also displayed excellent selectivity at hNET that appeared superior to those of reboxetine and atomoxetine (4 and 5).

Nonstimulants and emerging treatments in adults with ADHD.

CNS Spectr. 2008 Sep; 13(9 Suppl 13): 12-6, 1
Newcorn JH
Treatment of attention-deficit/hyperactivity disorder (ADHD) may positively impact the neurobiology of adult patients with ADHD. Treatment may also minimize impairment from core symptoms and may alter the course of co-morbid disorders such as depression and substance use disorder. However, much of the information on stimulant use in adult ADHD comes from studies conducted in children, and it remains unclear whether there is a difference between children and adults when it comes to the side effects and tolerability of ADHD treatments. It is known that clinical presentation differs between adults and children, with adults demonstrating a higher percentage of mood disorders. Current treatments for adult ADHD include psychosocial therapies and pharmacologic therapies, the latter of which include the stimulants d-methylphenidate extended release (XR), OROS methylphenidate, lisdexamfetamine, and mixed amphetamine salts XR; and the nonstimulant atomoxetine, a selective norepinephrine reuptake inhibitor. There is need for additional study of treatment strategies for adult ADHD. Although all classes of ADHD medications are approved in adults, there are fewer approved formulations for adults than for children. Efficacy in adults is more subjective than in children, which may affect how efficacy rates for adult treatments are calculated. Adults also present a greater diversion risk than children. In addition, there are several new and emerging medication treatments worth considering.

Treating adult ADHD with stimulants.

CNS Spectr. 2008 Sep; 13(9 Suppl 13): 8-11, 1
Stein MA
Treatment of attention-deficit/hyperactivity disorder (ADHD) may positively impact the neurobiology of adult patients with ADHD. Treatment may also minimize impairment from core symptoms and may alter the course of co-morbid disorders such as depression and substance use disorder. However, much of the information on stimulant use in adult ADHD comes from studies conducted in children, and it remains unclear whether there is a difference between children and adults when it comes to the side effects and tolerability of ADHD treatments. It is known that clinical presentation differs between adults and children, with adults demonstrating a higher percentage of mood disorders. Current treatments for adult ADHD include psychosocial therapies and pharmacologic therapies, the latter of which include the stimulants d-methylphenidate extended release (XR), OROS methylphenidate, lisdexamfetamine, and mixed amphetamine salts XR; and the nonstimulant atomoxetine, a selective norepinephrine reuptake inhibitor. There is need for additional study of treatment strategies for adult ADHD. Although all classes of ADHD medications are approved in adults, there are fewer approved formulations for adults than for children. Efficacy in adults is more subjective than in children, which may affect how efficacy rates for adult treatments are calculated. Adults also present a greater diversion risk than children. In addition, there are several new and emerging medication treatments worth considering.

 

This page was last reviewed by Dr Greg Mulhauser, Friday, 4 July 2008.

The URL of this page is:
http://counsellingresource.com/medications/trials-and-research/atomoxetine-research.html